Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed this Current Report on May 21, 2024, under Items 2.02, 7.01, and 9.01. The filing provides preliminary revenue expectations for the quarter ended December 31, 2023, and the quarter ended March 31, 2024, and announces an Investor and Analyst Research & Development Day.
Key Financial Metrics
| Period | Preliminary net revenue | Reported sources |
|---|---|---|
| Quarter ended December 31, 2023 | Approximately $12.1 million | Biomaterial product sales and biobanking services |
| Quarter ended March 31, 2024 | Approximately $14.8 million | Biomaterial product sales and biobanking services |
The filing does not provide preliminary figures for profit or loss, cash flow, margins, debt, liquidity, assets, or other financial metrics.
Material Changes Versus the Prior Comparable Period
Based on the preliminary amounts disclosed, net revenue increased by approximately $2.7 million, or approximately 22%, from the quarter ended December 31, 2023, to the quarter ended March 31, 2024. The filing does not provide a comparison with the first quarter of 2023 or other prior comparable periods.
Guidance, Outlook, Commentary, Risks, and Unusual Items
- The disclosed revenue amounts are unaudited and preliminary because the company had not finalized its fourth-quarter and full-year 2023 results or its first-quarter 2024 results.
- The audit of the year ended December 31, 2023, and the review of the quarter ended March 31, 2024, were ongoing and could result in changes to the disclosed revenue figures.
- Celularity announced an Investor and Analyst Research & Development Day for May 21, 2024, with business and research updates to be presented virtually and at its Florham Park, New Jersey headquarters.
- The related presentation was furnished as Exhibit 99.1 and was not deemed filed under Section 18 of the Exchange Act or incorporated by reference, except as expressly provided in a subsequent filing.
- The filing provides no formal financial guidance, profitability outlook, liquidity forecast, debt update, or quantified contingency.
Important Facts for Investors to Verify
- Verify final audited 2023 and reviewed first-quarter 2024 revenue in the company’s subsequent periodic filings.
- Determine whether the final results differ from the preliminary revenue estimates of $12.1 million and $14.8 million.
- Review final profitability, operating expenses, cash flow, cash balance, debt, and liquidity information, which are not included in this Form 8-K.
- Review Exhibit 99.1 and subsequent disclosures for the company’s research, development, commercial, and business outlook updates.